Literature DB >> 17694718

Psychiatric advance directives: a tool for consumer empowerment and recovery.

Anna M Scheyett1, Mimi M Kim, Jeffrey W Swanson, Marvin S Swartz.   

Abstract

Individuals with psychiatric disabilities identify choice and self-direction as central elements of recovery. During times of psychiatric crisis people may experience a frightening loss of choice and self-direction, which can be damaging and traumatic. Psychiatric advance directives (PADs) are legal documents created to address this loss of autonomy and choice during crises by allowing individuals to communicate in the present wishes for care during a future crisis. This paper examines the ways in which PADs support and can be a tool for recovery and discusses future recovery-oriented directions for PAD research and intervention.

Entities:  

Mesh:

Year:  2007        PMID: 17694718     DOI: 10.2975/31.1.2007.70.75

Source DB:  PubMed          Journal:  Psychiatr Rehabil J        ISSN: 1095-158X


  4 in total

1.  Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives.

Authors:  Christine M Wilder; Eric B Elbogen; Lorna L Moser; Jeffrey W Swanson; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2010-04       Impact factor: 3.084

Review 2.  Psychiatric advance directives and social workers: an integrative review.

Authors:  Richard A Van Dorn; Anna Scheyett; Jeffrey W Swanson; Marvin S Swartz
Journal:  Soc Work       Date:  2010-04

Review 3.  Patient and service-related barriers and facitators to the acceptance and use of interventions to promote communication in health and social care: a realist review.

Authors:  Gerard Leavey; Emma Curran; Deirdre Fullerton; Steven Todd; Sonja McIlfatrick; Vivien Coates; Max Watson; Aine Abbott; Dagmar Corry
Journal:  BMC Health Serv Res       Date:  2020-06-04       Impact factor: 2.655

4.  Psychiatric advance directives for people living with schizophrenia, bipolar I disorders, or schizoaffective disorders: Study protocol for a randomized controlled trial - DAiP study.

Authors:  Aurélie Tinland; Léa Leclerc; Sandrine Loubière; Frederic Mougeot; Tim Greacen; Magali Pontier; Nicolas Franck; Christophe Lançon; Mohamed Boucekine; Pascal Auquier
Journal:  BMC Psychiatry       Date:  2019-12-27       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.